Literature DB >> 171424

Herpesvirus antibodies and antigens in patients with cervical anaplasia and in controls.

A S Pacsa, L Kummerländer, B Pejtsik, K Pali.   

Abstract

Antibody activity to herpesvirus hominis type 2 (HVH-2) in 151 women cured of cervical carcinoma (60 in situ, 91 invasive) and in 106 controls differed significantly, especially between the in situ (73%) and control (17%) groups. Sera of 57 patients with cervical atypia showed an increased antibody activity to HVH-2 (58%), compared with that of the 57 matched controls (23%). Antibodies to cytomegalovirus (CMV) were detected more frequently in sera of women with atypia (61%) than in sera of women with cervical disorders other than atypia (42%) or in sera of healthy controls (33%). HVH antigens were present in cervical cells from patients with atypia and from matched controls. Not only exfoliated (imprints) but also cultured and cocultured cervical cells contained HVH antigens; there was no correlation between antigen positivity and antibody activity to HVH-2. Our data further supported the association between HVH-2 and cervical anaplasia and indicated that CMV may also be implicated in its etiology.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 171424     DOI: 10.1093/jnci/55.4.775

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  15 in total

Review 1.  The impact of inflationary cytomegalovirus-specific memory T cells on anti-tumour immune responses in patients with cancer.

Authors:  Xiao-Hua Luo; Qingda Meng; Martin Rao; Zhenjiang Liu; Georgia Paraschoudi; Ernest Dodoo; Markus Maeurer
Journal:  Immunology       Date:  2018-09-10       Impact factor: 7.397

Review 2.  Human cytomegalovirus and human herpesvirus 6 genes that transform and transactivate.

Authors:  J Doniger; S Muralidhar; L J Rosenthal
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

3.  Transformation of NIH 3T3 cells with cloned fragments of human cytomegalovirus strain AD169.

Authors:  J A Nelson; B Fleckenstein; D A Galloway; J K McDougall
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

4.  Multiple transforming regions of human cytomegalovirus DNA.

Authors:  T el-Beik; A Razzaque; R Jariwalla; R L Cihlar; L J Rosenthal
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

5.  Comparison of indirect hemagglutination and indirect immunofluorescence tests with microneutralization tests for detection of type-specific Herpesvirus hominis antibody.

Authors:  L D Johnson; D A Fuccillo; H Stalder; M A Oxman; C E Fraser; D L Madden
Journal:  J Clin Microbiol       Date:  1979-03       Impact factor: 5.948

6.  Molecular cloning of DNA sequences from cervical intraepithelial neoplasia that hybridize to human cytomegalovirus DNA.

Authors:  K Fletcher; J C Macnab
Journal:  Virus Genes       Date:  1989-08       Impact factor: 2.332

7.  Comparison of antibody-dependent cellular cytotoxicity and complement-dependent antibody lysis of herpes simplex virus-infected cells as methods of detecting antiviral antibodies in human sera.

Authors:  T Subramanian; W E Rawls
Journal:  J Clin Microbiol       Date:  1977-06       Impact factor: 5.948

8.  Herpesvirus-specific RNA and protein in carcinoma of the uterine cervix.

Authors:  J K McDougall; C P Crum; C M Fenoglio; L C Goldstein; D A Galloway
Journal:  Proc Natl Acad Sci U S A       Date:  1982-06       Impact factor: 11.205

9.  Class-specific herpes simplex virus antibodies in sera and cervical secretions from patients with cervical neoplasia: a multi-group comparison.

Authors:  G E Dale; R M Coleman; J M Best; B B Benetato; N C Drew; S Chinn; A O Papacosta; A J Nahmias
Journal:  Epidemiol Infect       Date:  1988-06       Impact factor: 2.451

10.  Characterization and location of myc homologous sequences in human cytomegalovirus DNA.

Authors:  E P Gelmann; D J Clanton; R J Jariwalla; L J Rosenthal
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.